125
Participants
Start Date
September 30, 2019
Primary Completion Date
March 31, 2032
Study Completion Date
June 15, 2032
Data-collection
Data will be collected on dose, total cumulative amount of dinutuximab beta per course, dose interruptions, dose discontinuations, prophylactic treatment, use of all concomitant analgesia, assessments of pain, and occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions and other AEs.
ACTIVE_NOT_RECRUITING
St. Anna Kinderkrebsforschung, Vienna
RECRUITING
Charité Berlin, Berlin
RECRUITING
Hôpital de la Timone, Hôpital des Enfants, Marseille
RECRUITING
IRCCS Istituto Giannina Gaslini, Genova
RECRUITING
Universitätsmedizin Greifswald, Greifswald
RECRUITING
Hospital Universitario y Politecnico La Fe Avenida Fernando Abril Martorell, Valencia
RECRUITING
Centre Oscar Lambret, Lille
ACTIVE_NOT_RECRUITING
Institut Curie, Paris
RECRUITING
Institut Gustave Roussy, Villejuif
RECRUITING
Uniwersytecki Szpital Dziecięcy, Krakow
RECRUITING
The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
ACTIVE_NOT_RECRUITING
Birmingham Children's Hospital, Birmingham
RECRUITING
University Hospital Southampton, Southampton
United BioSource, LLC
INDUSTRY
RECORDATI GROUP
INDUSTRY